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Patients with Highly Invasive Cutaneous Melanoma 
Need Selective, Focused Evaluations Before Surgery 
Perhaps President Reagan's experi-
ence with basal cell carcinoma will 
keep a few more palefaces out of the 
sun. The same caution-to stay away 
from UV light, although that is only 
one suspected cause-applies to cuta-
neous melanoma, the skin cancer 
that is more invasive, more difficult 
to control, and rising in incidence at 
a faster rate than almost any other 
cancer. 
Although the occurrence of cuta- Charles M. Balch 
neous melanoma is doubling every 
six to 10 years, the natural history of the disease has become 
somewhat less threatening in the last two decades, typical mela-
nomas being thinner, less invasive, and therefore more curable. 
A national survey of more than 4,500 melanoma patients treated 
during 1980 demonstrated that 87% of patients had clinically 
localized-that is, early-disease. In 39% of these patients, the 
melanomas were less than 0. 76 mm thick, a size associated with a 
90% or higher rate of cure. 
As Charles M. Balch, M.D., head of the Division of Surgery at 
UT MDAH, noted, "The natural history of this disease has 
changed dramatically and so must our treatment strategies and 
diagnostic approaches." 
Balch described the usual patient with melanoma as a man or 
woman with a fair complexion and a tendency to sunburn after 
relatively brief exposure to bright sunlight. A patient with mela-
noma has a 3 % to 5 % risk of developing a second primary mela-
noma and thus joins a "high-risk group of patients who should be 
followed for metastatic disease and second primary tumors." 
Patients with familial melanomas or with the dysplastic nevus 
syndrome are identifiable high-risk groups, Balch wrote in 
reviewing the clinical management of cutaneous melanoma in 
Texas Medicine (83:70-78, 1987). 
Balch advised physicians to obtain biopsies whenever they see 
subtle changes in any pigmented skin lesion, which may include 
growth in diameter or contour of a mole, change in color, bleed-
ing, itching, ulceration, development of a palpable lymph node, 
or a combination of these. A melanoma's features are "usually 
more subtle when it is in a more curable stage," he wrote. 
As to metastatic melanoma, no other cancer in humans has as 
variable a history because melanoma may spread to virtually any 
organ or tissue. But there are patterns. The regional lymph nodes 
are the most common sites of metastasis, and the most common 
first sites of distant metastasis are skin, subcutaneous tissue, and 
lung. Liver , bone, and brain are common sites of first relapse, 
Balch wrote. 
Selective Tests 
Instead of a broadside of tests, patients should at first undergo 
careful history-taking and physical examination, Balch advised. 
More expensive radiologic or nuclear scans are not indicated, he 
said, unless there are signs or symptoms suggestive of metastatic 
disease as discovered by a simple, cost-effective series of screening 
exams. The metastatic survey should be selective: 
• Chest roentgenogram for lung metastasis, which may be sus-
pected but usually has no symptoms-confirmed, if necessary, 
by lung tomograms or CT scan. 
• Serum alkaline phosphatase and lactic dehydrogenase assays 
and examination for liver mass or ascites in the case of liver 
symptoms of weight loss, anorexia, and upper abdominal 
pain-followed by liver sonar or abdominal CT scan if 
indicated. 
• Physical examination in the case of suspected subcutaneous or 
skin metastasis or second primary melanomas-followed by 
biopsy examination. 
• Complete history and physical examination for brain symp-
toms of headache, numbness, motor weakness, followed by 
brain CT scan if indicated. 
• Alkaline phosphatase assay for localized pain of bone metasta-
sis, and then bone scan and bone X-ray for confirmation. 
• Urinalysis for hematuria indicating kidney or bladder metasta-
sis, and then intravenous pyelogram or cytoscopic examination 
or both if indicated. 
Surgical Management 
Primary melanomas are removed by wide excision, except for 
lentigo maligna melanomas, which have a low recurrence rate 
continued on page 2 
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and do not need wide surgical margins. Overall, the primary mel-
anomas have a recurrence rate of only about 3%, although 
tumors with a thickness of 4 mm or more, ulceration, or location 
on foot, hand, scalp, or face have higher rates oflocal recurrence. 
Metastasis occurs most frequently in the regional lymph 
nodes, and it will be clinically evident from enlarged, firm, non-
tender nodes or be hidden as microscopic metastases in lymph 
nodes, Balch explained. 
In patients with clinically enlarged nodal metastases, the treat-
ment is radical lymphadenectomy because partial lymph node 
dissection or simple excision is inadequate. "Since the surgeon's 
ability to detect nodal metastases by clinical criteria is not opti-
mal," Balch noted, "a philosophy oflimited excision for only clin-
ically detectable nodes will often compromise both the palliative 
and curative goals of surgical treatment." 
Management of suspected microscopic metastases in the 
regional lymph nodes is more difficult, he explained, because the 
central question concerns the optimal timing of surgery. The 
procedure can be done immediately to remove any suspected 
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tumor, especially an intermediate-thickness melanoma measur-
ing up to 4 mm, or it can be delayed until nodal metastases are 
large enough to be detected by-palpat ion. 
After presenting all sides of the argument for early or for later 
surgical intervention, Balch noted that, since the cure rate for 
delayed lymph node dissection is so poor-25% survival at 10 
years-"many surgeons advocate immediate excision of the 
regional lymph nodes in selected patients to remove nodal micro-
metastases before they can disseminate. In this setting, surgical 
decisions depend on knowing which prognostic factors can reli-
ably identify patients at risk for occult metastatic disease." 
Balch is now principal investigator of a surgical trial that will 
involve more than 800 patients in 57 institutions in the United 
States and Canada and address issues of the most appropriate 
extent and timing of surgical intervention. More than 500 
patients are already participating in the study. 
Balch noted that, unfortunately, adjuvant therapy for regional 
metastasis of cutaneous melanoma, including immunotherapy, 
chemotherapy, and radiation therapy, have not been notably 
successful after operations. This underscores the need for regular 
follow-up examinations-every three to four months for the first 
two years, every six months through the fifth year, and yearly 
thereafter-to examine these patients for recurrent disease. 
Distant Metastasis 
For patients who have advanced melanoma, Balch explained, 
treatment depends on site and number of lesions, rate of growth, 
previous treatment, and the patient's age, overall condition, and 
wishes. Balch stressed consideration of the benefit-risk ratio of 
treatment intended to relieve the patient's symptoms, saying 
that the benefit-risk balance must be even stronger in the case of 
asymptomatic patients with distant metastases. Treatment 
choices include no treatment; surgical excision of the melanoma 
for palliative effect, which may be sustained for three to five years 
in some cases; palliative radiotherapy, which Balch said is effec-
tive for superficial metastatic disease of the skin or soft tissues 
where lesions can be treated with high-energy photon beams 
from a linear accelerator; chemotherapy and immunotherapy, 
which have their greatest potential benefit in patients with 
symptomatic visceral disease. 
Dacarbazine (DTIC), Balch pointed out, is the only drug cur-
rently available that has had significant activity in melanoma, 
most studies having shown 15% to 20% response rates. "Often," 
Balch said, "chemotherapy is used only in patients whose lesions 
are not amenable to surgery or radiation therapy, and only spar-
ingly in asymptomatic patients." 
Physicians who desire additional information may write Charles M. 
Balch, M.D., Division of Surgery, Box 112, The University of Texas 
M. D. Anderson Hospital and Tumor Institute at Houston 1515 
Holcombe Boulevard, Houston, Texas 77030. ' 
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Adjuvant Chetnotherapy ltnproves Survival of 
Patients with Stage II and III Breast Cancer 
The overall survival for breast can-
cer patients has improved in the last 
decade. According to Aman Buzdar, 
M.D., of the Medical Breast Unit at 
UT M. D. Anderson Hospital and 
Tumor Institute (UT MDAH), great 
progress has been made, especially 
for patients with stage II and III dis-
ease, thanks to the development of 
more aggressive adjuvant chemo-
therapy regimens. In addition, mod-
est gains have been made in patients Aman u Buzdar 
with disseminated disease. Buzdar, 
along with his colleagues at UT MDAH and other institutions, 
has been involved in several studies examining the effect on 
patient survival of alternating the drugs in a chemotherapy regi-
men, administering higher doses of drugs over a shorter period of 
time, and matching chemotherapy to certain pathologic prog-
nostic factors of the patient. 
According to Buzdar, the most aggressive chemotherapy regi-
men used to date is the combination of 5-fluorouracil, doxorubi-
cin (Adriamycin), and cyclophosphamide (FAC), with doxorubi-
cin being the most active agent of the combination. Studies in 
breast cancer treatment are currently evaluating ways to im-
prove the effectiveness of this regimen and seem to be meeting 
with success. 
Combination Chemotherapy 
Combination chemotherapy for the treatment of metastatic 
breast cancer has been proved effective in several studies con-
ducted by a diverse group of researchers. In 1985 Buzdar, along 
with Michael Ross, M.D., and their colleagues, published the 
results of a retrospective study that compared survival of patients 
with metastatic breast cancer for three decades: the 1950s, 1960s, 
and 1970s. The aim of the study was to determine if the use of 
combination chemotherap')' in the 19 Os had an im act on sur-
vival in patients with evidence of metastatic disease. Most of the 
patients in the 19 50s and the 1960s were treated with single-
agent chemotherapy, endocrine therapies, or both; by the 1960s, 
most were receiving single-agent chemotherapy. Patients in the 
1970s were predominantly treated with combination chemother-
apy regimens that usually included doxorubicin. 
The median survival time was 22 months for patients in the 
1970s and 12 months for patients in the 1960s; patients in the 
1960s did not have a significantly longer survival time than 
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patients in the 1950s. Although there were possible biases inher-
ent in the study, the results showed that patients treated in the 
1970s had an improvement in median survival of 9 to 12 months 
compared with patients treated in the previous two decades (see 
Fig. 1). Buzdar and his colleagues concluded that combination 
chemotherapy, though not significantly affecting mortality rates, 
definitely prolonged the survival of breast cancer patients. 
Recent studies show that median follow-up of patients treated 
in the late 1970s was 28-32 months, suggesting continued 
improvement in median survival for patients with metastatic dis-
ease. While there is currently only a slight potential for cure, 
Buzdar says "long-term unmaintained remissions do occur 
in about 3-4% of the patients with metastatic disease. We are 
keeping patients alive much longer with chemotherapies than 
















Fig. 1. Overall comparison 
of survival by decades. From 
M.B. Ross, A.U. Buzdar, T. L. 
Smith, et al. Cancer 1985; 
55:341-346. Reprinted with 
permission . 
Adjuvant Chemotherapy Trials 
Research has shown that the most effective use of chemother-
apy in high-risk patients (patients with stage II and III disease) is 
as an adjuvant to primary local treatments (surgery and irradia-
tion). In 1986, Buzdar and his colleagues published the results 
-f- a- tcen-year- aafl::l.-v-a-nt--€-hemer--her-ary---+F-i-a-1- feF-eFe-ast- E-anG@-I"--
patients. Beginning in 1974, patients with stage II and III disease 
received FAC chemotherapy after mastectomy (and in some 
cases after postoperative irradiation). The five-year survival for 
the study group was compared with the five-year survival for a 
consecutive series of patients with stage II and III disease seen at 
UT MDAH two years immediately preceding the initiation of 
the FAC trial (historical control group). The historical control 
continued on page 4 
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group did not receive systemic therapy following regional therapy 
until there was evidence of disease recurrence. 
The data for this ten-year follow-up trial clearly show that 
adjuvant chemotherapy (FAC combinations) was effective in 
reducing mortality in high-risk patients. In patients 50 years of 
age, the FAC combination was effective in reducing the mortality 
by 54%; in patients older than 50, the reduction in mortality was 
37%. (See Table 1 for a comparison of estimated disease-free sur-
vival rates for the study and control groups.) 
Subsequent prospective adjuvant FAC chemotherapy trials 
have also highlighted the relative ineffectiveness of postoperative 
irradiation and nonspecific immunotherapy with bacille 
Calmette-Guerin (BCG) and have confirmed the effectiveness of 
FAC regimens in improving patients' survival. NIH consensus 
data make it clear that tamoxifen has not been effective in reduc-
ing mortality in patients younger than 50 regardless of estrogen 
receptor (ER) status. In patients who were older than 50 and ER 
positive, however, the use of tamoxifen reduced mortality at 5 
years by 19%. 
Alternate Drugs and Shorter Therapy 
Researchers at UT MDAH have also examined the role of 
shorter-duration combination chemotherapy in their patients. 
"We used to continue chemotherapy for two years," says Buzdar, 
who with his colleagues at UT MDAH started an adjuvant che-
motherapy trial in 1980 that addressed the issues of shorter treat-
ment time and alternate drug combinations. It was their hope 
that the patient's survival could be improved by making the 
duration of treatment shorter and more intense and by altering 
the combination after a certain length of time. In the study 
(which has recently been completed with a five-year follow-up), 
vincristine and prednisone were added to the FAC therapy of 
patients with stage 11 and Ill disease; the patients received this 
chemotherapy for 6 months, after which all patients with ER-
TABLE 1 
Comparison of Estimated Disease-Free Survival and Survival 
Rates at 10 Years in First Study and Control Group 
Percent Percent 
Group Treatment Patients Disease-Free p Alive p* 
All pts FAC 222 49 <.01 55 <.01 
Control 186 33 <.01 34 <.01 
Stage II FAC 147 55 <.01 63 <.01 
Control 116 36 < .01 38 <.01 
Stage llI FAC 75 38 .02 41 .02 
Control 70 28 .02 26 . 02 
*p values were one-tailed test 
4 
positive or unknown status were randomized to receive either 
tamoxifen alone for 6 months or tamoxifen and additional che-
motherapy with methotrexate and vinblastine (TMV), which 
constituted a year of chemotherapy. All ER-negative patients 
received 6 months of additional chemotherapy with methotrex-
ate and vinblastine (MV). 
Patients with ER-positive tumors who received alternative che-
motherapy with additional drugs (TMV) had a lower risk of 
recurrence than patients who received tamoxifen following the 
initial chemotherapy phase; the difference in recurrence rate was 
not significant, however, when patients whose ER status was 
unknown were included in the analysis. ER-positive patients 
treated with additional alternate chemotherapy had superior 
disease-free survival compared with patients who received 
tamoxifen after completion of the FAC regimen . 
Patients with ER-negative disease treated with additional che-
motherapy had lower disease-free survival rates than those who 
had ER-positive disease. Buzdar notes that the addition of vin-
cristine and prednisone to the FAC combination did not 
enhance the therapeutic efficacy of the regimen. A summary of 
estimated disease-free survival at 5 years for patients in this study 
is shown in Table 2. 
TABLE2 
Summary of Estimated Disease-Free Survival at 5 Years by 
Estrogen Receptor Status and Maintenance Treatment of 
Third Study 
T TMV MV 
Patient 
Percent Percent Percent Character-
istics Pts. Disease-Free Pts. Disease-Free Pts. Disease-Free 
Total 122 66 113 73 101 64 
ER 
Positive 90 67 76 81 
Unknown 32 65 37 53 
ER = estrogen receptor status 
T = patients receiving tamoxifen 
TMV = patients receiving tamoxifen, methotrexate, and vinblastine 
MV = patients receiving methotrexate and vinblastine 
The Importance of ER Status 
With regard to the ER status of patients in these studies, 
Buzdar points out that similar observations have been reported 
by other investigators: in spite of adjuvant chemotherapy, 
patients with ER-negative tumors had inferior disease-free sur-
vival rates compared with the rates in patients with ER-positive 
tumors. Because ER-negative patients usually have more aggres-
sive disease, they tend to do poorly in comparison with ER-
positive patients . 
continued on page 8 
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Diagnostic Radiologists Use Expandable Metallic 
Stents for Sytnptotn Relief in Selected Patients 
A growing number of diagnostic 
radiologists are shifting the focus of 
their practice toward intervention. 
Interventional radiologists use vari, 
ous methods-for instance, direct 
chemotherapy to the tumor or block, 
ing of the tumor's blood supply-
to treat tumors that are too far ad, 
vanced for resection but confined to 
a local area. T heir main goal may not 
be to cure the cancer but to relieve 
the patient's symptoms and "get Cesare Gianturco 
him in shape" for further radio, or 
chemotherapy or surgery. Cesare 
Gianturco, M .D., an adjunct profes, 
sor in the Department of Diagnostic 
Radiology at The University of Texas 
M . D. Anderson Hospital and Tumor 
Institute at Houston, develops med, 
ic al inst ru ments with this aim 
in mind. 
Older Procedures 
Problematic Chusi/p Charnsangavej 
In the past, angioplasty or balloon dilatation has been 
employed to open tubular structures occluded by fibrosis or 
tumor. These procedures were problematic, however, because 
often after treatment the vessel would close again. Furthermore, 
surgery was required to rebuild the vessels. To combat these 
problems, in 1984 Gianturco invented the expandable metallic 
stent, a wire frame that bypasses or opens collapsed vessels and 
closed passages and then keeps them open. 
The Gianturco stent (Figure 1) is made of stainless steel wire 
0.0375 to 0.045 cm in diameter. The wire is first bent in a zigzag, 
and then its two ends are attached to one another, forming a 
cylindrical frame 2.5 to 3 cm in diameter. An extra wire, or barb, 
is soldered to the stent to prevent its migration. Depending on 
the length of wire used, the larger is the angle of the zigzags, the 
greater the diameter of the stent, and the stronger its expansile 
force. The stents are usually 2 to 3 cm long, but if a longer pas, 
sageway is needed, two or more stents can be connected to one 
another with a wire strut, forming a double or longer stent and 
spreading the expansile force without weakening it. Double 
stents also have barbs to keep them in place. 
The stent is placed in the patient's vein through a percutaneous 
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Fig. 1. The Gianturco expandable metallic stent. 
catheter. First the frame is compressed and slipped into the cathe, 
ter tube. Then the catheter is inserted normally into the vein in 
which the stent is to be placed. The stent is pushed out of the 
catheter into the vessel, where it expands, with an instrument 
called an introducer; the introducer holds the stent in place at 
the tip of the catheter while the catheter is withdrawn until the 
stent is released into the vessel. Since percutaneous placement 
is not a surgical procedure, the patient requires only a local anes, 
thetic. If the stent is to be placed in a patient's tracheo, bronchial 
tree, the same procedure is followed, but a bronchoscope is used 
instead of a catheter. 
Initial Tests Showed Promise 
The expandable metallic stents were initially tested in 1984 at 
The University of Texas System Cancer Center in experimental 
animals. The stents were placed in normal vessels first to gauge 
tissue reactions. Since the results of those experiments were 
encouraging, Chusilp Charnsangavej, M.D., and Sidney 
Wallace, M.D., of the Department of Diagnostic Radiology at 
UT MDAH, used five single stents to treat a patient for supe, 
rior vena cava syndrome and myocutaneous graft collapse 
in the tracheobronchial tree. The patient experienced immedi, 
ate symptom relief, although she died three weeks later of 
myelosuppression. 
Expandable metallic stents have been placed in 10 patients so 
far to treat stenosis of the superior vena cava or blockage of 
the tracheobronchial tree, and the results have been good in · 
every case but one, a patient with mediastinal osteogenic sar, 
coma metastases wrapping around the tracheobronchial tree. 
"The tumor was too hard to open up," Charnsangavej laments. 
In no case, however, have the stents caused clotting or thrombo, 
sis; in fact, new epithelium formed around every stent in the vena 
cavae, and mucosal secretions covered every stent in the tracheo, 
continued on page 6 
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continued from page 5 
bronchial trees. Charnsangavej speculates that the continual 
flow of blood over the stent is what keeps the vessels from devel, 
oping thromboses. 
Gianturco fashioned all of the first expandable metallic stents 
himself. He continues to make most of them now, but some labo, 
ratory technicians also build them. Charnsangavej expects that 
Cook, Inc., in Bloomington, Indiana, will eventually acquire the 
patent for the Gianturco stent. 
Use in Humans Still Experimental 
Until the United States Food and Drug Administration sane, 
tions the Gianturco stent, only physicians at UT MDAH may 
use it, under conditions approved by the UT MDAH Surveil, 
lance Committee. The FDA requires years of testing before 
it endorses a new product such as this one. Stents similar to 
Gianturco's are currently being utilized in Europe; by doctors in 
Portland, Oregon; and at Shadyside Hospital in Pittsburgh, 
Pennsylvania. 
Expandable metallic stents have also been tested, with favor, 
able results, in the bile ducts of dogs at the UT System Cancer 
Center, but they are not used in the bile ducts of patients here 
yet. Some physicians in Europe are placing such stents in human 
bile ducts, and they report positive results. At least four other 
groups are also interested in employing the Gianturco stents to 
treat bile duct occlusions. 
Researchers are now endeavoring to develop a stent similar to 
Gianturco's for use in arteries. Because arterial stents employ a 
balloon as well as the wire frame, they are called "balloon, 
assisted" expandable metallic graft stents. Gianturco himself is 
testing such a stent in dog arteries at UT MDAH. Arterial stents 
are also being tested in the coronary arteries of dogs at Emory 
University. 
Despite the success of the Gianturco stent, many questions 
remain. For instance, does the stent cause late complications? 
Although no late complications have been noted yet, the longest 
survival time so far is still only 6 months. How much expansile 
force does the stent need to exert? Too much force could cause the 
stent to perforate the structure, whereas too little force could 
keep the stent from making the tube patent. Can the extrinsic 
force that the stent must combat be measured? More experimen, 
tation is needed to answer these questions and confirm the good 
results seen up to now. 
Physicians who desire additional information may write Chusilp 
Charnsangavej, M.D., Department of Diagnostic Radiology, Box 57, 
The University of Texas M. D. Anderson Hospital and Tumor lnsti, 
tute at Houston, 1515 Holcombe Boulevard, Houston, Texas 77030. 
Nutritional and Psychological Aspects of 
Feeding Children Who Have Cancer 
by Cheryl Mokrzecky, 
M.S., R.D., L.D. 
Dietitian 
Nutrition and Food Service 
Because children with cancer are 
developing and maturing through, 
out their illness and treatment, their 
Nutritional Assessment 
At UT MDAH, nutritional status is assessed by a nutrition 
history and a combination of anthropometric and biochemical 
measures. Weight and height measurements, serum albumin lev, 
els, and a determination of current food intake are used for initial 
screening. For children, the primary anthropometric measure, 
ment is the ratio of weight to height, a measurement that relates 
~unmomrl 11eeds arc:quite--differen·r---+--+---------l- :------------t-- -----n-o-dy1nass-to~e~--his-measurerrrerrt is corr1parerr,-orrgrowtl1 
from those of healthy children and 
adults. Moreover, malnutrition at a 
time of rapid growth can cause physi, 
cal and intellectual delays in develop, Cheryl Mokrzecky 
ment as well as behavioral changes. The major factors that con, 
tribute to malnutrition in children with cancer are related to the 
disease, the side effects of treatment, and psychological factors 
such as family stress. Dietitians at UT M. D. Anderson Hospital 
(UT MDAH) work with patients and families to maintain op, 
timum nutritional status, growth, and development in the child. 
6 
grids, to standards developed by the National Center for Health 
Statistics (NCHS) for a reference population. Age is plotted 
along the axis, and height or weight values are plotted along the 
abcissa. This shows how children rank in size in relation to other 
children of the same age and sex. 
In our hospital, the dietitian uses the following weighHo, 
height percentage formula to identify patients at nutritional risk: 
Weight % = Patient's weight 
Height Patient's height 
X 100 _, 
s continued on page 7 
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where S = NCHS 50th percentile weight for age 
NCHS 50th percentile height for age 
Patients whose weighMo-height percentage is less than 90%, 
according to this formula, are considered at risk for malnutrition 
(Donaldson SS, Wesley WN, De Wys W, et al: A study of the 
nutritional status of pediatric patients. Am J Dis Child, in press). 
However, interpretation of a child's growth is best when 
observed over a period of time rather than from a single measure-
ment. Malnutrition should be suspected in any child who does 
not grow properly. 
Dietary evaluation, which is an important adjunct to clinical 
and biochemical assessment, provides information about the 
patient's current level of nutrient intake and family eating pat-
terns. It includes a nutrition history and food frequency determi-
nations, as well as information about the use of nutritional or 
vitamin supplements, vegetarianism, or other dietary practices 
that may suggest potential nutritional problems. 
There is no single biological parameter to assess nutritional sta-
tus, but dietitians at UT MDAH use measurement of serum 
albumin to evaluate the adequacy of a patient's protein status. 
Hypoalbuminemia may be an indicator of malnutrition. 
Patients who exhibit abnormalities in one or more nutritional 
parameters should be monitored frequently during treatment. 
Awareness of the fact that some tumors profoundly affect nutri-
tional status can aid in identifying patients who require early 
nutritional intervention. 
The incidence of malnutrition in patients with cancer tends to 
be highest in children who have advanced or metastatic disease. 
Moreover, children who are diagnosed with Ewing's sarcoma or 
neuroblastoma are at great risk for malnutrition. Adolescents, in 
general, may be at a high risk for malnutrition due to their 
increased metabolic requirements. 
Effects of Cancer and Cancer Treatment 
Most children with cancer undergo chemotherapy as their pri-
mary treatment. The agents used may produce severe gastroin-
testinal side effects such as nausea, vomiting, diarrhea, mucositis, 
and dysgeusia. During chemotherapy administration, children 
should be encouraged to take clear liquids such as gelatin des-
serts, broth, clear frozen desserts, and carbonated beverages, 
since these are usually well-tolerated on a queasy stomach. Fluids 
with electrolytes should be given to replace body fluids lost 
because of vomiting and diarrhea. Eating dry foods such as 
crackers or toast may help alleviate the feeling of nausea. 
The corticosteroid hormones, used alone or in combination 
with chemotherapy, also have adverse nutritional effects. These 
agents increase catabolism of lean body mass. Patients may have 
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difficulty in meeting the increased protein and calorie needs asso-
ciated with these agents, even though their appetites may 
increase. Finally, the fluid and electrolyte disturbances accompa-
nying steroid administration may cause edema that masks the 
loss of lean body mass. 
Eating Disorders 
A child's eating may also be affected by less obvious factors 
such as family stress, depression, or a struggle for control within 
the family. 
When a child has cancer, the family's normal routine is dis-
rupted in many ways. Parents often have to function separately, 
since one parent may continue to work and care for siblings at 
home while the other parent stays with the sick child in the hos-
pital. The stress imposed by this situation may magnify problems 
that existed before the child's illness. 
Families often participate in a child's health care by feeding the 
child. Since weight loss and cachexia represent illness and nor-
mal growth signifies health, parents may become preoccupied 
with their child's eating. Extreme concern about a child's weight 
may mask the parent's fear that the child will die. If the child's 
normal eating pattern is disrupted, the parent often feels hope-
less, having lost influence in an activity that he or she had been 
able to control before the child's illness. As the parent experi-
ences a sense of failure, efforts to force the child to eat increase. 
Unfortunately, the focus on eating may actually depress the 
child's appetite and food intake. 
Struggles for control in pediatric patients, especially in adoles-
cents, may be manifested in eating disorders. Children with can-
cer sometimes develop anorexia nervosa in a subconscious 
attempt to reduce their feelings of dependence and loss of free-
dom and individuality. Some patients use eating as a way to gain 
attention from their parents. 
Nutritional Support During Therapy 
Nutritional support using oral supplements, tube feedings, or 
parenteral nutrition can prevent weight loss and aid in maintain-
ing or regaining nutritional status. 
Meeting the nutritional needs of anorectic children with ade-
quate quantities of nourishing food can be a challenge. If a child 
has one or more of the following problems, he or she may need 
nutritional supplementation: 
1. Arrest in expected weight gain 
2. Evidence of malnutrition as indicated by abnormal 
biochemical parameters 
3. Difficulty chewing or swallowing food 
4. Persistent nausea and vomiting 
5. Inadequate dietary intake 
continued on page 8 
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Breast Cancer 
continued from page 4 
Conclusions 
Currently at UT MDAH, Buzdar and his colleagues are evalu-
ating the role of high-dose intensification with autologous bone 
marrow support in patients with metastatic disease. Patients are 
initially treated with doxorubicin combinations (FAC). After 
two or three cycles of chemotherapy, patients who show a com-
plete or partial response have their bone marrow extracted and 
stored. These patients are treated with an additional few cycles of 
the FAC regimen and high-dose chemotherapy with bone mar-
row support. This study is currently ongoing and is being con-
ducted with UT MDAH's bone marrow transplant team. 
Patients with stage II and III disease are currently being entered 
in a prospective study comparing the efficacy of tamoxifen 
administration for five years with the FAC regimen. In stage I 
patients (with negative nodes) they are evaluating four cycles of 
doxorubicin chemotherapy compared with no further treatment 
after local therapy. 
Physicians who desire additional information may write Aman U. 
Buzdar, M.D., Department of Medical Oncology, Box 78, The 
University of Texas M. D. Anderson Hospital and Tumor Institute at 
Houston, 1515 Holcombe Boulevard, Houston, Texas 77030. 
Feeding Children Who Have Cancer ... 
continued from page 7 
High-protein, high-calorie foods such as peanut butter, nuts, 
cheeses, milkshakes, instant breakfast, or nutritional supple-
ments can provide concentrated sources of nutrients. Small, fre-
quent feedings may be more effective in increasing total intake. 
Acceptance of nutritional supplements may depend on the 
patient's taste perception. The senses of taste and smell may be 
affected by treatment, and foods that children enjoyed prior to 
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treatment may lose their appeal or taste bad. Children then asso-
ciate those foods with the side effects of treatment and avoid 
them. These are called learned food aversions. In view of this 
phenomenon, dietitians at UTMDAH frequently encourage 
children to consume their favorite foods only while they are feel-
ing well. 
When all efforts to support a child's nutritional status through 
the oral route have failed, nutrition via the enteral route is the 
preferred method of feeding, if the gastrointestinal tract is func-
tional. When compared to parenteral nutrition, enteral feedings 
have a lower risk of complications and are less expensive. Tube 
feedings given during the night and discontinued during the day 
can allow the child to carry on normal daily activities. Tube feed-
ing formulas for children over two years of age can be chosen 
from the enteral products for adults. Intolerance to a tube feed-
ing may be manifested by nausea, vomiting, diarrhea, abdominal 
cramping, or bloating. These can usually be alleviated by adjust-
ing the rate or the strength of the feeding; however, continued 
intolerance may require a change in formula. Feedings may be 
administered as a continuous infusion by a pump or as bolus 
feedings given over a period of 20-30 minutes. 
Parenteral nutrition may be given to replenish or maintain 
nutritional status when the gastrointestinal tract is dysfunc-
tional. However, arenteral nutrition is more costly and re uires 
more complex monitoring than enteral feeding. 
Providing aggressive nutritional support as soon as nutritional 
deterioration is detected or anticipated can prevent malnutri-
tion. It is much easier to minimize or prevent malnutrition than 
to reverse a severely malnourished state. Children who are able 
to maintain adequate nutrition throughout their therapy feel 
better, have fewer complications, and are able to continue che-
motherapy with fewer delays (van Eys J, Cancer Res, 1982; 
42(Suppl): 74 75-7515). 
Physicians who desire additional information may write Nutrition 
and Food Service, Box 58, The University of Texas M. D. Anderson 
Hospital and Tumor Institute at Houston, 1515 Holcombe Boulevard, 
Houston, Texas 77030. 
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